OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Rettig on the Evolving Use of Triplet Regimens in mHSPC

March 10th 2023

Matthew Rettig, MD, discusses the evolution of triplet therapy within the landscape of metastatic hormone-sensitive prostate cancer, as well as the importance of considering key prognostic factors when utilizing this approach.

Dr. Johnson on the Importance of Diverse Representation in Breast Cancer Clinical Trials

March 10th 2023

Nathalie McDowell Johnson, MD, FACS, discusses the importance of diverse representation in breast cancer clinical trials.

Dr. Kaklamani on CDK4/6 Inhibition Prior to Elacestrant in ER+/HER2– Breast Cancer

March 10th 2023

Virginia Kaklamani, MD, discusses the utilization of elacestrant following treatment with CDK4/6 inhibitors in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer.

Dr. Nair on Using Yoga to Improve Quality of Life in Patients Undergoing Breast Cancer Treatments

March 10th 2023

Nita Nair, MBBS, DNB, MCh, discusses research evaluating the role of yoga as a way to improve the quality of life of patients undergoing breast cancer treatments.

Dr. Ligon on Delivering CAR T-cell Therapy via Mediport Lines in Pediatric B-Cell Malignancies

March 10th 2023

John Ligon, MD, discusses findings from a study investigating the use of mediports to deliver CAR T-cell therapy in patients at Pediatric Real-World CAR Consortium medical centers.

Dr. Shah on Zamto-cel in R/R DLBCL

March 10th 2023

Nirav N. Shah, MD, discusses findings from a preplanned interim futility analysis of the single-arm phase 2 DALY II USA trial in patients with relapsed/refractory diffuse large B-cell lymphoma.

Dr. Mascarenhas on the Benefit of Fedratinib in Myelofibrosis

March 9th 2023

John Mascarenhas, MD, discusses the benefit of fedratinib for patients with myelofibrosis.

Dr. Villalona-Calero on KB-0742 in Solid Tumors and NHL

March 9th 2023

Miguel Villalona-Calero, MD, discusses the unique mechanism of action of the CDK9 inhibitor KB-0742 in patients with relapsed/refractory solid tumors or non-Hodgkin lymphoma.

Dr. Wainberg on the Rationale for the Phase 3 NAPOLI 3 Trial in Patients With PDAC

March 9th 2023

Zev A. Wainberg, MD, discusses the rationale behind the phase 3 NAPOLI 3 trial in patients with metastatic pancreatic ductal adenocarcinoma.

Dr. Torka on BTK Inhibitors Available for Patients With R/R MCL

March 9th 2023

Pallawi Torka, MD, discusses the BTK inhibitors available for treatment of patients with relapsed/refractory mantle cell lymphoma.

Dr. Zhang on Key Phase 3 Trials for PARP Inhibitors in mCRPC

March 8th 2023

Tian Zhang, MD, MHS, discusses key phase 3 trials evaluating PARP inhibitors in the treatment of metastatic castration-resistance prostate cancer.

Dr. Pavlick on the IGNYTE Trial in Patients With Melanoma Following Anti–PD-1 Progression

March 8th 2023

Anna C. Pavlick, DO, discusses the phase 2 IGNYTE trial examining vusolimogene oderparepvec in combination with nivolumab in 3 tumor-specific cohorts, including 1 featuring patients with anti–PD-1–failed cutaneous melanoma.

Dr. Mascarenhas on the Role of Pacritinib in Myelofibrosis

March 8th 2023

John Mascarenhas, MD, discusses the role of pacritinib in patients with myelofibrosis.

Dr. Hussain on Retrospective Analysis of the ARASENS trial in mHSPC

March 8th 2023

Maha H. Hussain, MD, FASCO, FACP, discusses key efficacy and safety data from a secondary analysis of the phase 3 ARASENS trial in metastatic hormone-sensitive prostate cancer.

Dr. Godara on Treatment Strategies Following First Relapse in Multiple Myeloma

March 8th 2023

Amandeep Godara, MBBS, discusses the current treatment strategies following first relapse for patients with multiple myeloma.

Dr. Brahmer on Treatment Following Progression on First-line Immunotherapy in NSCLC

March 8th 2023

Julie Renee Brahmer, MD, discusses clinical trials investigating treatment options for patients with non–small cell lung cancer following progression after first-line immunotherapy.

Dr. Galsky on the Rationale for the CheckMate-274 Trial in Urothelial Cancer

March 8th 2023

Matthew Galsky, MD, discusses the rationale of the phase 3 CheckMate-274 trial in patients with urothelial cancer.

Dr. Tombal on Darolutamide Monotherapy in Newly Diagnosed mHSPC

March 8th 2023

Bertrand Tombal, MD, PhD, discusses the rationale for conducting a phase 2 study of darolutamide monotherapy in newly diagnosed metastatic hormone-sensitive prostate cancer.

Dr. Torka on the Role of Pirtobrutinib in R/R MCL

March 8th 2023

Pallawi Torka, MD, discusses the clinical implications of the FDA approval of pirtobrutinib in patients with relapsed or refractory mantle cell lymphoma.

Dr. Owen on Choosing Between BTK Inhibitors in CLL

March 8th 2023

Carolyn Owen, MD, FRCPC, discusses factors to consider when deciding whether to use the BTK inhibitors ibrutinib, acalabrutinib, or zanubrutinib in patients with chronic lymphocytic leukemia.